Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials.

Zhang, Zhishan; Pan, Qunxiong; Lu, Mingdong; Zhao, Bin

Zhang, Zhishan; Pan, Qunxiong; Lu, Mingdong; Zhao, Bin.

Afiliação

Zhang Z; Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.
Pan Q; Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.
Lu M; The Second Affiliated Hospital & Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
Zhao B; Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.

EClinicalMedicine ; 63: 102156, 2023 Sep.

Article em En | MEDLINE | ID: mdl-37600482

Palavras-chave

Biomarker; Cancer; Immunotherapy; Overall survival; Surrogate endpoint

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies / Systematic_reviews Idioma: En Revista: EClinicalMedicine Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google